Swiss exports to US surge in September as pharma shipments rise ahead of tariff threat

Swiss exports to the United States rebounded sharply in September, surging nearly 43% in nominal, seasonally adjusted terms, primarily driven by pharmaceutical companies accelerating shipments. This increase was a strategic response to pre-empt potential U.S. tariffs, following an August decline caused by earlier duties and amid President Trump's threat of a 100% tariff on branded pharmaceutical products, which has not yet been implemented. The significant jump in chemical and pharmaceutical exports, which constitute over half of all Swiss goods exports, underscores companies' proactive supply chain adjustments in anticipation of evolving trade policy risks.

Analysis

Swiss exports to the United States experienced a significant rebound in September, surging nearly 43% month-over-month in nominal, seasonally adjusted terms. This sharp increase follows an August decline triggered by previously imposed 39% U.S. tariffs. The primary catalyst for this September surge was pharmaceutical companies accelerating shipments to pre-empt potential future U.S. tariffs, particularly a threatened 100% duty on branded pharmaceutical products.

While initial August tariffs exempted pharmaceutical products, President Trump's late-September threat of a 100% tariff, effective October 1st unless U.S. manufacturing is established, prompted proactive supply chain adjustments. This strategic move by pharma firms, including major players like Roche and Novartis who anticipate exemption due to U.S. expansion plans, highlights the industry's sensitivity to evolving trade policy. The overall Swiss exports also rose by 3.4% in September, indicating broader positive movement.

The chemical and pharmaceutical sector, which constitutes over half of all Swiss goods exports, saw its exports jump 5.1% in September, underscoring its critical role in the overall rebound. This short-term boost, driven by tariff anticipation rather than organic demand, suggests a pull-forward of sales. The non-implementation of the 100% tariff threat, as Trump presses for lower drug prices, introduces ongoing uncertainty regarding future trade relations and pharmaceutical pricing policies.

Key Decisions for Investors

• Investors should closely monitor U.S. trade policy developments, particularly regarding pharmaceutical tariffs and the ongoing pressure for lower drug prices, as these could significantly impact Swiss pharma companies' future revenue streams and supply chain strategies.
• Recognize that the September export surge likely represents a pull-forward of demand in anticipation of tariffs, suggesting potential moderation or even decline in subsequent months if the tariff threat fully subsides or is implemented differently.
• Assess the resilience and U.S. expansion plans of major Swiss pharmaceutical companies like Roche and Novartis, as their ability to adapt to potential tariffs or establish U.S. manufacturing will be crucial for long-term performance.